Incannex Receives HREC Approval for Phase 2 Clinical Trial Assessing IHL-675A for use in Treatment of Pain and Function in Rheumatoid Arthritis
13 juil. 2023 08h00 HE
|
Incannex Healthcare
Highlights: Incannex has received approval from HREC for the lead site, Emeritus Research, Camberwell, VIC for the Phase 2, Blinded, Placebo Controlled Clinical Trial to Determine the Effect on Pain...
Dr. Fatima Cody Stanford, Associate Professor of Medicine and Pediatrics at Harvard Medical School, Joins Clearmind Medicine's Scientific Advisory Board
11 juil. 2023 08h30 HE
|
Clearmind Medicine Inc.
Tel Aviv, Israel/Vancouver, Canada, July 11, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the "Company"), a biotech company focused on discovery...
Incannex Announces Intention to Redomicile to United States, List all Shares on Nasdaq
10 juil. 2023 07h30 HE
|
Incannex Healthcare
Highlights: Incannex to redomicile to the United States via a Scheme of Arrangement pursuant to Australian lawA newly formed Delaware corporation (Incannex Healthcare Inc.) will become the ultimate...
Psychedelic Therapeutics Market Grow at a CAGR 14.92 % from 2023 to 2031 | Exclusive InsightAce Report
27 juin 2023 10h20 HE
|
InsightAce Analytic Pvt. LTd.
Jersey City, NJ, June 27, 2023 (GLOBE NEWSWIRE) -- InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the “Global Psychedelic Therapeutics Market Size, Share &...
Incannex Announces Participation at the H.C. Wainwright 4th Annual Neuropsychiatry Virtual Conference June 26, 2023
23 juin 2023 08h00 HE
|
Incannex Healthcare
MELBOURNE, Australia, June 23, 2023 (GLOBE NEWSWIRE) -- Incannex Healthcare Limited (Nasdaq: IXHL) (ASX: IHL), (‘Incannex’ or the ‘Company’) a pharmaceutical company developing medicinal cannabinoid...
Incannex Appoints Principal Investigators for IHL-42X Phase 2/3 Clinical Trial
16 juin 2023 08h00 HE
|
Incannex Healthcare
MELBOURNE, Australia, June 16, 2023 (GLOBE NEWSWIRE) -- Incannex Healthcare Limited (Nasdaq: IXHL) (ASX: IHL), (‘Incannex’ or the ‘Company’) a clinical-stage pharmaceutical company developing unique...
Beckley Waves Establishes Ethics Council to Guide Industry Standards and Best Practices During Inaugural Summit of The World’s Leaders in Psychedelics
01 juin 2023 09h00 HE
|
Beckley Waves
The New Ethics Council will Work Alongside Beckley Waves to set the Standard for Sustainable and Ethical Operations in the Burgeoning Psychedelics Sector Experts Involved in the Council Include Paul...
Silo Pharma Commences Study of Novel Joint Homing Peptide SPU-21
30 mai 2023 09h00 HE
|
Silo Pharma, Inc.
Phase 2 of study will further investigate the peptides’ method, optimization, and binding affinity in human tissue ENGLEWOOD CLIFFS, NJ, May 30, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq:...
Incannex Company Presentation – Presentation of Psychennex, Psychedelic Therapies Subsidiary Company
16 mai 2023 07h50 HE
|
Incannex Healthcare
MELBOURNE, Australia, May 16, 2023 (GLOBE NEWSWIRE) -- Incannex Healthcare Ltd (Nasdaq: IXHL) (ASX: IHL) (‘Incannex’ or ‘the Company’) is pleased to announce a company presentation which details...
Silo Pharma to Present at Psychedelic Drug Development Conference
24 avr. 2023 08h15 HE
|
Silo Pharma, Inc.
ENGLEWOOD CLIFFS, NJ, April 24, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional...